Core Insights - KalVista Pharmaceuticals reported strong early commercial traction for its oral treatment EKTERLY for hereditary angioedema (HAE), with significant revenue growth and positive patient feedback since its U.S. launch in July 2025 [3][4][6]. Financial Performance - The company reported $49.1 million in net product revenue from launch through December 31, 2025, including $35.4 million in the fourth quarter [3][15]. - Operating loss for the transition period was $112 million, with SG&A expenses rising to $124.7 million, while the company ended the period with approximately $300 million in cash and investments [5][18]. - Total operating expenses were $160.2 million compared to $117 million in the prior-year period [15][17]. Market Adoption - As of February 28, KalVista had 1,702 patient start forms and 724 unique prescribers, with refills representing the majority of units and revenue, indicating strong ongoing utilization of EKTERLY [2][6]. - The adoption rate among high-burden patients is around one-third and continues to grow quarter over quarter [7]. International Expansion - KalVista is expanding EKTERLY access internationally, with a strong start in Germany and recent launch activities in Japan [8]. - The company anticipates a geographic revenue mix of approximately 85% from the U.S. and 15% from international markets over time [9]. Clinical Data and Future Plans - Clinical data from the KONFIDENT extension showed that sebetralstat was chosen for over 84% of attacks, with high patient satisfaction ratings [6][11]. - Plans for a pediatric NDA submission for children ages 2 to 11 are set for the third quarter of 2026, with potential U.S. launch in 2027 [13]. - The company is exploring short-term prophylaxis use around procedures, with encouraging results from initial trials [14].